Spots Global Cancer Trial Database for leukaemia
Every month we try and update this database with for leukaemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia | NCT01615809 | Invasive Pulmon... Lymphoblastic L... Myeloblastic Le... Lymphoblastic L... Myeloblastic Le... | AMPHOTERICIN B | 3 Years - 17 Years | Fundació Sant Joan de Déu | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant | NCT01941680 | T-cell Lymphoma Leukaemia | 18 Years - 75 Years | University Hospital Center of Martinique | ||
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Leukemia Cell Cultures for Research of New Anti-Cancer Therapies | NCT00993538 | Acute Leukaemia | Blood sampling Bone marrow asp... | 28 Days - | University Hospital, Strasbourg, France | |
| Leukemia Cell Cultures for Research of New Anti-Cancer Therapies | NCT00993538 | Acute Leukaemia | Blood sampling Bone marrow asp... | 28 Days - | University Hospital, Strasbourg, France | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | NCT03911128 | Leukemia, Acute... | Observational | 0 Years - 45 Years | Karolinska University Hospital | |
| PUMA (Paediatric Osseous Marrow Assessment) | NCT03466944 | Leukaemia | 5 Years - 24 Years | Institute of Cancer Research, United Kingdom | ||
| High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant | NCT01941680 | T-cell Lymphoma Leukaemia | 18 Years - 75 Years | University Hospital Center of Martinique | ||
| Leukemia Cell Cultures for Research of New Anti-Cancer Therapies | NCT00993538 | Acute Leukaemia | Blood sampling Bone marrow asp... | 28 Days - | University Hospital, Strasbourg, France | |
| High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant | NCT01941680 | T-cell Lymphoma Leukaemia | 18 Years - 75 Years | University Hospital Center of Martinique | ||
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. | NCT02108951 | Philidelphia Po... | Nilotinib | 18 Years - | Novartis | |
| Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) | NCT00989261 | Acute Myeloid L... | Compound AC220 | 18 Years - 85 Years | Daiichi Sankyo | |
| A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | NCT03911128 | Leukemia, Acute... | Observational | 0 Years - 45 Years | Karolinska University Hospital | |
| PUMA (Paediatric Osseous Marrow Assessment) | NCT03466944 | Leukaemia | 5 Years - 24 Years | Institute of Cancer Research, United Kingdom | ||
| Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality | NCT00179621 | Myelodysplastic... | Lenalidomide 5 ... Lenalidomide 10... Placebo | 18 Years - | Celgene | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY) | NCT05473325 | Diabetes Chronic Kidney ... Cancer Bowel Disease Cardiovascular ... Mononucleosis Flu Heart Diseases HIV Infections AIDS and Infect... Bulimia Chest Infection... Arthritis Leukaemia Alcoholic Liver... Allergies Alzheimer Disea... Appendicitis Eczema Bronchitis Cellulitis Cirrhosis Depression Gout High Cholestero... Indigestion Obesity Osteoporosis | 18 Years - | Willows Health | ||
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT) | NCT02310997 | Leukaemia Lymphoma Other Haematolo... | Umbilical Cord ... Cyclophosphamid... Total body irra... Busulfan Melphalan Fludarabine | 28 Days - 45 Years | University College, London |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
